Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
A daily pill to treat covid could be just months away, scientists say

A daily pill to treat covid could be just months away, scientists say

Potential covalent SARS-CoV-2 spike protein inhibitors

Potential covalent SARS-CoV-2 spike protein inhibitors

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Scientists identify potential therapeutic targets to alleviate severe COVID-19 in aged patients

Scientists identify potential therapeutic targets to alleviate severe COVID-19 in aged patients

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Atopic dermatitis may stem from poorly regulated sex hormones, study suggests

Atopic dermatitis may stem from poorly regulated sex hormones, study suggests

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

SARS-CoV-2 variants show substantial differences in spike structure

SARS-CoV-2 variants show substantial differences in spike structure

The comparative effectiveness of neutralizing monoclonal antibodies against SARS-CoV-2

The comparative effectiveness of neutralizing monoclonal antibodies against SARS-CoV-2

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

Novel combination therapy may prolong viral suppression in patients with HIV

Novel combination therapy may prolong viral suppression in patients with HIV

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.